Abstract | AIM: In the present study, the anticancer efficacy of a novel escheriosome-based formulation of PLK1-specific siRNA was evaluated against liver cancer in BALB/c mice. MATERIALS & METHODS: The escheriosome-based siRNA nanoparticles were prepared using lipids isolated from Escherichia coli. The escheriosomes were characterized for size, surface charge and stability. The anticancer potential of PLK1-specific siRNA formulation was ascertained on the basis of expression of pro-/anti-apoptotic factors and histopathological studies. RESULTS: The escheriosome-entrapped siRNA was found to be released in surrounding milieu in a sustained manner. The nanoformulation was successful in modulating proapoptotic factors and eventually helped in better survival of the treated animals. CONCLUSION: Our data demonstrate the efficacy of systemically administered siRNA in the treatment of experimental liver cancer. This novel therapeutic strategy may be applicable to a broad range of cancers in patients with the obstinate form of the disease.
|
Authors | Arun Chauhan, Swaleha Zubair, Ahmad Nadeem, Sajid Ali Ansari, Mohammad Yunus Ansari, Owais Mohammad |
Journal | Nanomedicine (London, England)
(Nanomedicine (Lond))
Vol. 9
Issue 4
Pg. 407-20
(Apr 2014)
ISSN: 1748-6963 [Electronic] England |
PMID | 24910873
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cell Cycle Proteins
- Lipids
- Proto-Oncogene Proteins
- RNA, Small Interfering
- Protein Serine-Threonine Kinases
- polo-like kinase 1
|
Topics |
- Animals
- Cell Cycle Proteins
(genetics)
- Drug Delivery Systems
- Escherichia coli
(chemistry)
- Female
- Genetic Therapy
- Lipids
(chemistry, isolation & purification)
- Liver
(pathology)
- Liver Neoplasms
(genetics, pathology, therapy)
- Mice
- Mice, Inbred BALB C
- Nanoparticles
(chemistry)
- Protein Serine-Threonine Kinases
(genetics)
- Proto-Oncogene Proteins
(genetics)
- RNA Interference
- RNA, Small Interfering
(administration & dosage, genetics, therapeutic use)
|